AlphAIalphai — Financial news for AI agents
financialcontent.comJUL 273 min read$BUSE

First Busey (BUSE) Reports Earnings Tomorrow: What To Expect

First Busey (NASDAQ: BUSE) will report earnings Tuesday afternoon. The company last quarter reported revenue of $197.2 million, up 40.1% year on year, and beat analysts on EPS and tangible book value per share. For the upcoming quarter, analysts expect revenue growth of 2.6% y/y. The average analyst price target is $30.57 versus $29.85.

Original reporting
financialcontent.com
Published Jul 27, 2026, 4:00 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 27, 2026, 4:28 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
First Busey (BUSE) Reports Earnings Tomorrow: What To Expect — source image
Source · financialcontent.com
Decision brief

The 30-second read

$BUSENeutralMed
01

Why it matters

Traders can use the stated consensus (2.6% YoY revenue growth) and the company’s recent revenue-estimate miss pattern to frame expectations for the earnings print and potential volatility.

02

Market read

Provides a near-term earnings catalyst date plus consensus and recent miss context for BUSE, but no new earnings/guidance data.

03

What to watch

The preview does not include guidance, credit quality, NIM, or deposit trends, which are typically the key drivers of regional bank earnings reactions.

Relevance 4/10Novelty 4/10Timing: Ahead of Tuesday afternoon earnings release.

Background

The article is an earnings preview for First Busey, referencing last quarter’s revenue beat and the current quarter’s consensus growth.

Company-level read

Ticker impact

$BUSENeutralMedium confidence
Context

First Busey is scheduled to report results Tuesday afternoon, with consensus revenue growth of 2.6% YoY and prior misses noted.

Expected impact

Likely volatility around revenue and EPS versus the low-growth consensus, with downside risk if another revenue miss occurs.

Evidence & confidence

The article provides specific consensus growth, recent miss history, and the timing of the earnings release, but it does not disclose any new post-close datapoint or guidance change.

Market effects

Sector

Regional banks earnings cadence may influence sentiment, but this piece is primarily a single-name earnings setup.

Regional

Limited, as it does not introduce new regional credit or funding developments.

Global

Low, no cross-market macro or policy linkage beyond general earnings expectations.

Counterpoint

What could challenge this read

If BUSE’s tangible book value and EPS have been beating recently, the market may be positioned for a miss and could react more positively to any stabilization in revenue.

Key entities

  • company
    First Busey

    Regional banking company reporting earnings Tuesday afternoon; consensus expects 2.6% YoY revenue growth.

  • peer
    OFG Bancorp

    Peer cited as having reported Q2 revenue growth of 4.5% and a post-results stock move.

  • peer
    Hilltop Holdings

    Peer cited as having reported Q2 revenues up 7.5% and a post-results stock move.

Read at source← All news

Related articles

JUL 28
$BUSEMed

FIRST BUSEY CORP /NV/ (BUSE): Results of Operations and Financial Condition

FIRST BUSEY CORP /NV/ (BUSE) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 buse_20260728x26q2xex991.htm EX-99.1 Document F I R S T B U S E Y C O R P O R A T I O N A N N O U N C E S 2 0 2 6 S E C O N D Q U A R T E R E A R N I N G S Q 2 | 2 0 2 6 www.busey.com INVESTOR CONTACT: Tate McKay, Director of Investor Relations and Corporate Development

SEC EDGAR 8-K6 min
MAY 27
$BUSEMedAI 9/10

First Busey (NASDAQ:BUSE) Hits New 12

First Busey (NASDAQ:BUSE) reached a new 52-week high on Wednesday, trading up to $27.78 and last at $27.4010 versus a prior close of $27.08. The bank reported Q1 EPS of $0.67 (vs. $0.57 consensus) on revenue of $197.17 million. It also declared a $0.26 quarterly dividend and analysts cited a $27.50 consensus target.

dailypolitical.com4 min
AUG 8
$NNNMed

NNN REIT Q2 Earnings Call Highlights

NNN REIT (NYSE:NNN) reported Q2 earnings call highlights. It cut its full-year bad-debt outlook to about 40 bps from 60 bps, kept second-half credit-loss assumptions, and raised the annual disposition guidance midpoint by $10 million to $140 million. In Q2 it invested $290M in 89 properties, occupancy rose to 99.1%, and it declared a $0.62/share dividend.

yahoo.com6 min
AUG 8
$NTRMed

Nutrien Q2 Earnings Call Highlights

Nutrien’s CEO Ken Seitz said the company used automation to mine 53% of ore tons in the first half, exceeding its 2024 target range. Nutrien maintained 2026 potash shipment guidance of 74-77 million tons and 2026 nitrogen sales-volume guidance of 9.2-9.7 million tons. Q2 nitrogen adjusted EBITDA was $635 million. The company cut 2026 capex guidance to $1.95B-$2.05B and raised share repurchases to about $75M/month.

yahoo.com6 min
AUG 8
$NVGSMed

Navigator Q2 Earnings Call Highlights

Navigator Holdings (NYSE:NVGS) reported Q2 updates. Its 2026 all-in cash breakeven rose to $21,990 per vessel per day from $21,230, citing the pending sale of eight Unigas Pool vessels. Morgan’s Point ethylene terminal set a record 374,278 tonnes; Navigator’s equity income was $7.1m. It sold Navigator Pegasus for $30.5m and expects Unigas sales net proceeds about $129m and book gains $65m-$70m. Dividend $0.07/share; Q3 TCE and volumes expected to moderate.

yahoo.com6 min
AUG 8
$NUVBMed

Nuvation Bio Q2 Earnings Call Highlights

Nuvation Bio (NUVB) reported Q2 call highlights for IBTROZI in ROS1-positive lung cancer, citing TRUST-I results in TKI-naive patients with a 90% objective response rate and 50-month median response duration and progression-free survival. The company said first-line ROS1 TKI use rose nearly 20% through May 2026. It also updated safusidenib Phase II J201 (52% ORR, 79% 36-month PFS) and outlined Phase III/G307 and G209 studies. Cash was $661M after a June convertible notes offering.

yahoo.com6 min